GreenPeptide Co., Ltd. announced the initiation of a phase II clinical trial of the cancer peptide vaccine GRN-1201with the concomitant use of an immune checkpoint antibody against non-small cell lung cancer (NSCLC) in the United States. GRN-1201 is a cancer peptide vaccine that consists of peptides derived from 4 cancer antigen proteins and recognizes HLA-A2, which is a common HLA type in Americans and Europeans. The company is conducting phase I clinical trial of GRN-1201 targeted to melanoma in the United States and have obtained safety information to initiate this second study. This time, a newly launch a phase II clinical trial of the concomitant use of GRN-1201 with an immune checkpoint antibody (an anti-PD-1 antibody preparation). The therapeutic effect of immunity is expected to be enhanced further by the concomitant use of a cancer vaccine that activates immune functions and an immune checkpoint antibody that removes the brakes on the immune system. This trial is scheduled to be performed as an open label study with the overall response rate (ORR) as a primary endpoint from 2017 to 2019.